Statins, as the main medication for the prevention and treatment of cardiovascular diseases, is often related with large individual differences in their effectiveness and toxicity, and some people might develop statin-related myopathy of different severity, which often leads to poor drug compliance with statins and even withdrawal of statins, and then leads to increased cardiovascular events and mortality. Statins related gene polymorphism is known to be responsible for the observed individual response differences, in which solute carrier organic anion transporter family member 1B1 (SLCO1B1) and apolipoprotein E (ApoE) gene polymorphism could significantly affect the safety and efficacy of statins. SLCO1B1 and ApoE gene polymorphisms can be detected by real-time fluorescent polymerase chain reaction (PCR), chip hybridization, sequencing, Sanger sequencing and other methods. Detection of SLCO1B1 and ApoE gene polymorphisms before medication will help realize the precision drug use of statins, improve the efficacy of lipid-regulating therapy, and reduce or avoid the occurrence of adverse drug reactions. Laboratory Medicine Committee of Chinese Association of Integrated Medicine, Clinical Immunodiagnosis Professional Committee of Zhejiang Immunology Society and Therapeutic Drug Monitoring Research Professional Committee of Zhejiang Pharmacological Society organized related experts to discuss the detection and clinical application of statins related gene polymorphism, and the consensus views are achieved and summarized in this document, 10 recommendations are formulated to help the safe and rational use of statins on the basis of SLCO1B1 and ApoE gene polymorphisms detection results.

Statins; Apolipoproteins E; Gene polymorphism; Myopathy; Organic anion transport protein 1